Spectral AI, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Spectral AI received FDA De Novo clearance in May 2026 for its DeepView System for burn indication, enabling commercial distribution in the U.S. The company was awarded $31.7M in advanced funding from BARDA in March 2026 and drew $6.5M under its Avenue Capital credit facility in Q2 2026. Q2 2026 revenue declined to $3.5M (vs. $5.1M YoY) due to cost-share provisions under the BARDA contract following FDA clearance. Net loss was $(4.2)M or $(0.13)/share; cash position $14.0M at June 30, 2026. Company targets first commercial sales by year-end 2026 but provides 2026 revenue guidance of ~$18.5M, excluding material DeepView product sales.
Why this rating
FDA clearance + $31.7M BARDA funding are transformational de-risking events for pre-revenue company; $14M cash ~20% of market cap provides runway. Material relative to $72M size, but commercial execution risk remains high.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.